Key facts
- This page summarizes Benjamin L. Oakes's Form 3 filing for Scribe Therapeutics, Inc. (SCTX).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 23 Jul 2026, 21:20.
Benjamin L. Oakes - 23 Jul 2026 Form 3 Insider Report for Scribe Therapeutics, Inc. (SCTX)
- Reporting relationship
- President, CEO, Director, Chairman of the Board
- Issuer ticker
- SCTX
- Reported as of
- 23 Jul 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 23 Jul 2026, 21:20:56 UTC
- Prior SEC filing
- 27 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Benjamin Oakes
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Benjamin L. Oakes filed Form 3 for Scribe Therapeutics, Inc. (SCTX) on 23 Jul 2026.
Change
- Previous filing in this sequence was filed on 27 Jul 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002127814
Primary reporting owner
Oakes Benjamin L.
- Relationship
- President, CEO, Director, Chairman of the Board
- Address
- C/O SCRIBE THERAPEUTICS INC., 1150 MARINA VILLAGE PARKWAY, ALAMEDA
- Signature
- /s/ Benjamin Oakes
- Signature date
- 23 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SCTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 506,602
- Date
- 23 Jul 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SCTX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 23 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,330
- Exercise price
- $3.08
- Footnotes
- F1
SCTX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 23 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 101,320
- Exercise price
- $6.40
- Footnotes
- F1
SCTX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 23 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,462
- Exercise price
- $6.40
- Footnotes
- F2
SCTX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 23 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,969
- Exercise price
- $19.13
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option is fully vested.
Footnote F2
The option vested as to 25% of the award on January 1, 2026, and the remaining 75% of the option will vest in equal monthly installments thereafter until such time as the options are 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.